Aequus Pharmaceuticals (AQS) Stock Price, News & Analysis

Company Overview

Aequus Pharmaceuticals Inc. operates as a specialty pharmaceutical company in Canada. The company markets ZIMED PF, a preservative-free bimatoprost ophthalmic solution. It also develops a range of prescription-free dry eye products under the OPTASE name; and REV-0100 for the treatment of stargardt disease. The company was incorporated in 2013 and is headquartered in Vancouver, Canada.

Key Stats

• Today's Range: C$0.01 to C$0.01
• 50-Day Range: C$0.01 to C$0.01
• 52-Week Range: C$0.01 to C$0.04
• Volume: 25,000 shs
• Average Volume: 95,565 shs
• Market Capitalization: C$663,150.00
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: N/A
• Consensus Rating: N/A

AQS Stock Analysis - Frequently Asked Questions

How have AQS shares performed this year?

Aequus Pharmaceuticals' stock was trading at C$0.01 at the beginning of the year. Since then, AQS stock has decreased by 50.0% and is now trading at C$0.01.
View the best growth stocks for 2025 here.

How do I buy shares of Aequus Pharmaceuticals?

Shares of AQS stock and other Canadian stocks can be purchased through an online brokerage account. Popular online brokerages with access to the Canadian stock market include BMO InvestorLine, CIBC Investor's Edge, Desjardins Online Brokerage, HSBC InvestDirect, Laurentian Bank Discount Brokerage, National Bank Direct Brokerage, Qtrade Investor, Questrade, RBC Direct Investing, Scotia iTrade, TD Direct Investing, and Virtual Brokers.

What other stocks do shareholders of Aequus Pharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Aequus Pharmaceuticals investors own include GrowLife (PHOT), Unrivaled Brands (TRTC), Acorn Energy (ACFN), Crown Castle (CCI), LiCo Energy Metals (LIC), Marijuana Company of America (MCOA) and Rogers (ROG).

Industry, Sector and Symbol

• Stock Exchange: CVE
• Sector: Medical
• Industry: Drug Manufacturers - Specialty & Generic
• Sub-Industry: N/A
• Current Symbol: CVE:AQS
• CIK: N/A
• Web: www.aequuspharma.ca
• Phone: +1-604-3367906
• Fax: N/A
• Employees: 12
• Year Founded: N/A

Profitability

• EPS (Most Recent Fiscal Year): C($0.01)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: C$-2,860,000.00
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: -1,569.60%
• Return on Assets: -178.79%

Debt

• Debt-to-Equity Ratio: 138.88
• Current Ratio: 0.07
• Quick Ratio: 0.46

Sales & Book Value

• Annual Sales: C$1.17 million
• Price / Sales: 0.57
• Cash Flow: C$0.00 per share
• Price / Cash Flow: 5.00
• Book Value: C($0.04) per share
• Price / Book: -0.13

Miscellaneous

• Outstanding Shares: 132,630,000
• Free Float: N/A
• Market Cap: C$663,150.00
• Optionable: Not Optionable
• Beta: -0.02